Skip to main content
🩹DERMATOLOGY

Skin & Genetic Skin Disease

Vitiligo, psoriasis, atopic dermatitis, epidermolysis bullosa β€” from managing symptoms to repigmentation and topical gene therapy

~125 million people with psoriasis; ~230 million with atopic dermatitis; ~70 million with vitiligo; rare genodermatoses affect thousands
CURE AVAILABLE
55/ 100
TO BROAD CURE

MILESTONEVyjuvek gene therapy is approved for epidermolysis bullosa; ruxolitinib cream helps vitiligo.

LATESTVyjuvek topical gene therapy became commercially available.

An approved cure exists for a major form of this disease Β· Not medical advice.

CURRENT STATUS

The first topical gene therapy β€” Vyjuvek β€” is now FDA-approved and applied at home for dystrophic epidermolysis bullosa. Topical and oral JAK inhibitors deliver repigmentation in vitiligo and rapid clearance in atopic dermatitis; TYK2 inhibitors and IL-23 biologics clear psoriasis. AI-guided biomarker work is ending trial-and-error prescribing.

KEY BREAKTHROUGHS

Vyjuvek (beremagene geperpavec) β€” first FDA-approved topical, redosable gene therapy, delivering COL7A1 for dystrophic epidermolysis bullosa

Ruxolitinib cream (Opzelura) β€” first topical JAK inhibitor to achieve meaningful repigmentation in vitiligo

Deucravacitinib (Sotyktu) β€” first oral TYK2 inhibitor for plaque psoriasis

IL-13/IL-4 and IL-23 biologics (dupilumab, risankizumab) transforming atopic dermatitis and psoriasis

AI-COMPRESSED PIPELINE

AI TOOLS ACCELERATING CURES

Dermatology Image Deep-LearningSkin Organoid ModelingBiomarker Response PredictionCRISPR / HSV Vector Design

KEY ORGANIZATIONS

Krystal BiotechIncyteBristol Myers SquibbPfizerLEO Pharma

KEY CLINICAL TRIALS

Vyjuvek (B-VEC) Label Expansion & At-Home Gene Therapy

View

Krystal Biotech

A redosable topical gene therapy using an engineered HSV-1 vector to deliver functional COL7A1 to the skin of people with dystrophic epidermolysis bullosa, restoring type VII collagen and healing chronic wounds β€” applied at home.

πŸ‘₯ Approved with ongoing pediatric/from-birth label expansion studiesπŸ“ US β€” EB specialty centers

Topical & Oral JAK Inhibitors for Vitiligo Repigmentation

View

Incyte / academic

Trials extending JAK inhibition (topical ruxolitinib and oral agents), often combined with phototherapy, to drive durable repigmentation across more of the body surface in vitiligo.

πŸ‘₯ Multiple Phase 2/3 vitiligo studiesπŸ“ US, EU β€” multicenter

TIMELINE ESTIMATE

Psoriasis / atopic dermatitis control & vitiligo repigmentation: available now. Broader gene therapy for genodermatoses: 3–7 years. Durable vitiligo cure: 4–8 years.

EXPLORE FULL CURE PROTOCOL